Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Firefly Neuroscience (AIFF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to 684.54%.

  • Firefly Neuroscience's EBITDA Margin rose 122366800.0% to 684.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 1450.52%, marking a year-over-year increase of 96048900.0%. This contributed to the annual value of 618.07% for FY2023, which is 5689100.0% down from last year.
  • Per Firefly Neuroscience's latest filing, its EBITDA Margin stood at 684.54% for Q3 2025, which was up 122366800.0% from 546.49% recorded in Q2 2025.
  • In the past 5 years, Firefly Neuroscience's EBITDA Margin ranged from a high of 6247.27% in Q4 2024 and a low of 12921.21% during Q3 2024
  • Its 5-year average for EBITDA Margin is 2414.74%, with a median of 69.38% in 2022.
  • Data for Firefly Neuroscience's EBITDA Margin shows a peak YoY increase of 144946400bps (in 2024) and a maximum YoY decrease of -126143600bps (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Firefly Neuroscience's EBITDA Margin stood at 52.28% in 2021, then grew by 2bps to 51.38% in 2022, then crashed by -15951bps to 8247.37% in 2023, then surged by 176bps to 6247.27% in 2024, then crashed by -111bps to 684.54% in 2025.
  • Its EBITDA Margin stands at 684.54% for Q3 2025, versus 546.49% for Q2 2025 and 4802.33% for Q1 2025.